SCHEMBL18239682

SCHEMBL18239682

CCOC(=O)NCCOc1ccc2c(c1)c(CCNC(=O)CC)c(C)n2S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.43
MTNR1A P48039 8/20 0.43
MTNR1B P49286 4/20 0.43
HTR6 P50406 1/20 0.41
PTGDR Q13258 1/20 0.41
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA9 Q16790 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18239831 0.92 MAPT (0.44) MAPTPTGDR2MTNR1AMTNR1BHTR6
SCHEMBL18222517 0.86 HTR6 (0.56) PTGDR2MTNR1AMTNR1BHTR6PTGDR
SCHEMBL18239688 0.85 HTR6 (0.45) MAPTPTGDR2MTNR1AMTNR1BHTR6
SCHEMBL18222515 0.84 PTGDR2 (0.48) MAPTPTGDR2MTNR1AMTNR1BHTR6
SCHEMBL18222548 0.83 PTGDR2 (0.40) MAPTPTGDR2MTNR1AMTNR1BHTR6
SCHEMBL18222509 0.83 PTGDR2 (0.40) MAPTPTGDR2MTNR1AMTNR1BHTR6
SCHEMBL18222512 0.81 PTGDR2 (0.51) MAPTPTGDR2MTNR1BHTR6PTGDR
SCHEMBL18800080 0.80 MTNR1A (0.46) MTNR1AMTNR1B
SCHEMBL18239789 0.80 PTGDR2 (0.46) MAPTPTGDR2MTNR1AMTNR1BHTR6
SCHEMBL18239857 0.77 PTGDR2 (0.44) MAPTPTGDR2MTNR1AMTNR1BHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637451-B2 Indole compound ASTELLAS PHARMA INC. (JP) 2017-05-02 US disclosed
US-20160332966-A1 INDOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332966-A1 INDOLE COMPOUND MTNR1A, MTNR1B, IDO2 MAPT 887/4885PTGDR2 86/4885MTNR1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.